SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Lyn Benson who wrote (22607)6/23/1998 9:15:00 AM
From: Henry Niman  Respond to of 32384
 
Here's an earlier paper on non-steroidal progestin mimics:

J Med Chem 1998 Jan 29;41(3):303-310

5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents.

Edwards JP, West SJ, Marschke KB, Mais DE, Gottardis MM, Jones TK

Department of Medicinal Chemistry, Ligand Pharmaceuticals, Inc., San Diego, California 92121, USA. jedwards@ligand.com

Several 5-(4-chlorophenyl)-1,2-dihydro-5H-chromeno[3,4-f]quinolines were prepared to determine the effects of substitution at C(8) and C(9) on the progestational activity of this pharmacophore. In combination with a halogen (F or Cl) at C(9), replacement of the C(5) aryl group with variously substituted aryl groups resulted in optimization of the progestational activity, affording compounds with in vitro activity greater than that of progesterone as measured by a cotransfection assay using human progesterone receptor subtype-B (hPR-B). Binding affinities (Ki) to hPR-A were subnanomolar in many cases. These in vitro effects were verified in vivo using a rodent model. Compound 10 (LG120794, 9-chloro-5-(4-chlorophenyl)-1,2-dihydro-2,2,4-trimethyl-5H-chromeno++ +[3,4-f] quinoline) was more potent than medroxyprogesterone acetate at counterpoising the effects of estradiol benzoate in the uterine wet weight assay using immature rats.

PMID: 9464361, UI: 98125637




To: Lyn Benson who wrote (22607)6/23/1998 9:26:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Lyn, I think that LGND is beginning to pound the table. Sunday's NY Times article on Designer Estrogens didn't do much, but now LGND has grabbed the lead in the Designer Progestin area. Soon they will be out with Neupogen mimics and the street will begin to catch on.